nuvaring and Weight-Gain

To compare the adverse effects, cycle control, and metabolic effects of NuvaRing and a combined oral contraceptive (COC).. Women seeking contraception received NuvaRing (n = 300) or a COC (n = 300) for 12 cycles in a randomized, open-label trial.. The total number of women with adverse effects did not differ significantly between the 2 groups. Leucorrhea, vaginitis, decreased libido, and ring-related problems were more common with NuvaRing, whereas weight increase, acne, and emotional lability were more common with the COC. Breakthrough bleeding occurred in 11.3% of women receiving NuvaRing and in 14.7% of women receiving the COC; 2.1% and 2.9% of women, respectively, had no withdrawal bleeding. Differences in blood pressure, blood sugar levels, lipid profile, liver enzyme activity, and anticoagulant activity were not statistically significant, with the exception of low-density lipoprotein levels measured at 6 and 12 months, which were significantly lower in the NuvaRing group than in the COC group.. NuvaRing is a good alternative to a COC. It is associated with a slightly reduced incidence of breakthrough bleeding and there were no clinically relevant adverse effects or changes in blood pressure, blood sugar levels, lipid profile, or anticoagulant activity when compared with the COC.

Topics: Acne Vulgaris; Adolescent; Adult; Affective Symptoms; Androstenes; Contraceptive Devices, Female; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Desogestrel; Drug Combinations; Ethinyl Estradiol; Female; Humans; Leukorrhea; Libido; Lipoproteins, LDL; Metrorrhagia; Vaginitis; Weight Gain; Young Adult

Oral contraceptives could induce mood changes. As far as our knowledge, there are no studies in literature that have examined the role of vaginal contraception in self-perceived body image.. To evaluate the effects of intravaginal contraception on weight gain and perceived body image in relation with the Beck's Depression Inventory questionnaire (BDI) and the McCoy Female Sexuality Questionnaire (MFSQ).. Twenty-one adult (18-35 years old) eumenorrheic (menstrual cycle of 25-35 days), lean (body mass index - BMI - of 19-25 kg/m. BMI, FRS, MFSQ and BDI.. After 6 months of therapy with NuvaRing®, both body weight (60.0 ± 8.3; p = 0.050) and BMI (22.1 ± 3.1; p = 0.028) slightly, but statistically, increased. FRS and BDI showed no differences after the vaginal contraception. Hormonal contraception was associated with a significant decrease in the two-factor Italian MFSQ score.. Vaginal ring seems a good alternative to other hormonal contraceptive not significantly altering the female sexuality and not influencing the FRS and BDI.

Topics: Adolescent; Adult; Body Dysmorphic Disorders; Body Mass Index; Contraceptive Devices, Female; Desogestrel; Drug Combinations; Ethinyl Estradiol; Female; Health Knowledge, Attitudes, Practice; Humans; Italy; Overweight; Pilot Projects; Prospective Studies; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Weight Gain; Young Adult